FDA OKs Onyx’s Kyprolis for multiple myeloma

WASHINGTON (Reuters) – U.S. drug regulators approved Onyx Pharmaceuticals Inc’s Kyprolis for people with a type of blood cancer that has failed to respond to other medicines. The U.S. Food and Drug Administration said on Friday the intravenous drug was approved for treating multiple myeloma in people who have tried at least two other medicines, including Takeda Pharmaceutical Co Ltd’s Velcade and Celgene Corp’s Revlimid or Thalomid. Multiple myeloma, a type of cancer that affects the plasma cells in bone marrow, is relatively rare in the United States but often deadly. …